General Pharmacology — MCQs

General Pharmacology Indian Medical PG Practice Questions and MCQs

Question 421: Which of the following immunosuppressive agents acts selectively by inhibiting helper T-cells?

A. Cyclophosphamide
B. Azathioprine
C. Cyclosporine (Correct Answer)
D. Cytosine arabinoside

Explanation: **Explanation** **Correct Option: C. Cyclosporine** Cyclosporine is a **calcineurin inhibitor**. Its primary mechanism of action involves binding to an intracellular protein called **cyclophilin**. This complex inhibits calcineurin, a phosphatase required for the dephosphorylation and activation of the **Nuclear Factor of Activated T-cells (NFAT)**. Without active NFAT, the transcription of **Interleukin-2 (IL-2)** is blocked. Since IL-2 is the primary cytokine responsible for the proliferation and differentiation of **Helper T-cells (CD4+)**, cyclosporine acts selectively on this cell population without significantly affecting B-cells or causing bone marrow suppression. **Incorrect Options:** * **A. Cyclophosphamide:** An alkylating agent that cross-links DNA. It is non-selective and cytotoxic to all rapidly dividing cells, including B-cells and T-cells, often causing significant myelosuppression. * **B. Azathioprine:** A purine antimetabolite (prodrug of 6-mercaptopurine) that inhibits DNA synthesis. It affects both T and B lymphocyte proliferation non-selectively. * **D. Cytosine arabinoside (Cytarabine):** A pyrimidine antimetabolite used primarily in chemotherapy (AML). It inhibits DNA polymerase and is not used as a selective immunosuppressant for T-cells. **High-Yield NEET-PG Pearls:** * **Drug of Choice:** Cyclosporine is a cornerstone for preventing graft-versus-host disease (GVHD) in organ transplants. * **Side Effects:** Remember the "6 H's": **H**ypertension, **H**irsutism, **H**yperplasia of gums, **H**yperlipidemia, **H**yperkalemia, and **H**epatotoxicity. * **Nephrotoxicity:** This is the most important dose-limiting toxicity. * **Metabolism:** It is metabolized by **CYP3A4**; therefore, grapefruit juice (inhibitor) increases its toxicity.

Question 422: Which of the following statements about orphan drugs is true?

A. Drugs used for orphans
B. Drugs used for rare diseases (Correct Answer)
C. Easily available drugs
D. Drugs with excessive financial benefits

Explanation: ### Explanation **Correct Option: B. Drugs used for rare diseases** Orphan drugs are biological products or medicines intended for the diagnosis, prevention, or treatment of **rare diseases** (e.g., Cystic Fibrosis, Gaucher’s disease, Leprosy). These diseases affect a very small percentage of the population. Because the market for these drugs is so limited, pharmaceutical companies are often reluctant to develop them under normal marketing conditions, as the cost of research and development would not be recovered through sales. To encourage their production, governments provide incentives like tax credits, patent extensions, and simplified marketing authorization. **Analysis of Incorrect Options:** * **A. Drugs used for orphans:** This is a literal misinterpretation. The term "orphan" refers to the status of the drug (lacking a "sponsor" or commercial interest), not the parental status of the patient. * **C. Easily available drugs:** Orphan drugs are often difficult to access due to limited production, high costs, and the specialized nature of the conditions they treat. * **D. Drugs with excessive financial benefits:** In reality, these drugs are **commercially non-viable** without government subsidies or incentives because the target patient population is too small to generate significant profit. **High-Yield Facts for NEET-PG:** * **Examples of Orphan Drugs:** Digoxin-specific antibody (Digibind), Fomepizole (for Ethylene glycol poisoning), Thalidomide (for Leprosy) [1], and various monoclonal antibodies for rare cancers. * **Criteria:** In the USA, a rare disease is defined as one affecting fewer than 200,000 people. * **Incentives:** The **Orphan Drug Act (1983)** provides 7 years of market exclusivity to the manufacturer.

Question 423: All of the following are indications for eicosanoids or their inhibitors EXCEPT:

A. Abortion
B. Essential hypertension (Correct Answer)
C. Patent ductus arteriosus
D. Transposition of the great arteries

Explanation: **Explanation:** The correct answer is **Essential Hypertension** because eicosanoids (prostaglandins) and their inhibitors are not standard or first-line treatments for this condition. While some prostaglandins have vasodilatory properties, they are not used clinically for essential hypertension due to their short half-life and significant side effects. **Analysis of Options:** * **Abortion:** Prostaglandin analogues like **Misoprostol (PGE1)** and **Dinoprostone (PGE2)** are used for medical termination of pregnancy and cervical ripening because they stimulate uterine contractions. * **Patent Ductus Arteriosus (PDA):** NSAIDs (eicosanoid inhibitors) like **Indomethacin** or **Ibuprofen** are the treatment of choice to close a PDA in neonates by inhibiting the synthesis of PGE2, which normally keeps the ductus open. * **Transposition of the Great Arteries:** In cyanotic heart defects, **Alprostadil (PGE1)** is used to **maintain** the patency of the ductus arteriosus. This allows for life-saving mixing of oxygenated and deoxygenated blood until surgical correction can be performed. **High-Yield Clinical Pearls for NEET-PG:** 1. **PGE1 (Alprostadil):** Used for maintaining PDA and treating erectile dysfunction. 2. **PGE1 Analogue (Misoprostol):** Used for NSAID-induced peptic ulcers and postpartum hemorrhage (PPH). 3. **PGF2α (Latanoprost):** First-line treatment for Open-Angle Glaucoma (increases uveoscleral outflow). 4. **PGI2 (Epoprostenol):** Used in Pulmonary Arterial Hypertension. 5. **TXA2 (Thromboxane):** Potent vasoconstrictor and platelet aggregator; inhibited by low-dose Aspirin for cardioprotection.

Question 424: Which of the following drugs is not given sublingually?

A. Isosorbide dinitrate
B. Buprenorphine
C. Ergotamine tartrate
D. Isosorbide-5-mononitrate (Correct Answer)

Explanation: **Explanation:** The sublingual route is preferred for drugs that require a rapid onset of action or those that undergo extensive first-pass metabolism in the liver. **Why Isosorbide-5-mononitrate (ISMN) is the correct answer:** Isosorbide-5-mononitrate is the active metabolite of Isosorbide dinitrate. Unlike its parent compound, ISMN has **100% oral bioavailability** and does not undergo significant first-pass metabolism. Therefore, there is no pharmacological advantage to giving it sublingually. It is primarily used for the chronic prophylaxis of angina pectoris via the oral route. **Analysis of incorrect options:** * **Isosorbide dinitrate (ISDN):** This drug undergoes extensive first-pass metabolism (bioavailability <25%). The sublingual route bypasses the liver, allowing for rapid relief (within 2–5 minutes) during an acute anginal attack. * **Buprenorphine:** This is a potent opioid used for pain and opioid de-addiction. It has high first-pass metabolism if swallowed, making the sublingual route the standard for systemic absorption. * **Ergotamine tartrate:** Used in the treatment of acute migraine attacks, it is given sublingually to ensure rapid absorption and to bypass the gastric stasis often associated with migraine. **High-Yield NEET-PG Pearls:** * **Drugs commonly given sublingually:** Nitroglycerin (GTN), Isosorbide dinitrate, Buprenorphine, Desmopressin, Nifedipine (though no longer recommended for hypertensive emergencies), and Ergotamine. * **Advantages:** Bypasses the liver (First-pass metabolism), avoids destruction by stomach acid, and provides rapid onset of action. * **ISMN Fact:** It has a longer half-life than ISDN, making it suitable for twice-daily oral dosing but unsuitable for emergency use.

Question 425: Which of the following is NOT a non-sedating antiallergic drug?

A. Cetirizine
B. Astemizole
C. Terfenadine
D. Triprolidine (Correct Answer)

Explanation: ### Explanation The question asks to identify the drug that is **not** a non-sedating antihistamine. Antihistamines (H1-receptor antagonists) are classified into two generations based on their ability to cross the blood-brain barrier (BBB) and their sedative potential. **1. Why Triprolidine is the Correct Answer:** Triprolidine is a **First-Generation H1-antihistamine** belonging to the alkylamine class. First-generation antihistamines are highly lipophilic and readily cross the BBB. Once in the central nervous system (CNS), they block H1 receptors involved in wakefulness, leading to significant **sedation** and psychomotor impairment. They also possess significant anticholinergic properties. **2. Why the Other Options are Incorrect:** * **Cetirizine (Option A):** A potent second-generation antihistamine (metabolite of Hydroxyzine). While it is technically "non-sedating" because it has poor CNS penetration, it is known to cause mild drowsiness in a small percentage of patients compared to other second-generation drugs. * **Astemizole (Option B) & Terfenadine (Option C):** These are classic second-generation antihistamines. They are highly polar and do not cross the BBB, making them non-sedating. *Note: Both were withdrawn from many markets due to the risk of QT prolongation and Torsades de Pointes when co-administered with CYP3A4 inhibitors.* **3. NEET-PG High-Yield Pearls:** * **Second-Generation Characteristics:** High H1 selectivity, no anticholinergic side effects, and minimal sedation. Examples include Fexofenadine, Loratadine, and Desloratadine. * **Fexofenadine:** The active metabolite of Terfenadine; it is considered the "most" non-sedating as it does not cross the BBB at all. * **Clinical Caution:** Avoid combining Terfenadine/Astemizole with Ketoconazole or Erythromycin due to the risk of fatal arrhythmias (hERG channel blockade). * **First-Generation Uses:** Due to their sedative and anticholinergic effects, they are used for motion sickness (Promethazine, Cyclizine) and as OTC sleep aids (Diphenhydramine).

Question 426: Which of the following characteristics is associated with a high volume of distribution for a drug?

A. Lipophilicity (Correct Answer)
B. Hydrophilicity
C. High protein binding
D. Low therapeutic index

Explanation: The **Volume of Distribution ($V_d$)** is a theoretical volume that relates the amount of drug in the body to its plasma concentration ($V_d = \text{Total amount of drug} / \text{Plasma concentration}$).1. Why Lipophilicity is Correct:Lipophilic (fat-soluble) drugs easily cross biological membranes and leave the vascular compartment to enter peripheral tissues and adipose stores [2]. Because the drug sequestered in tissues is not present in the plasma, the plasma concentration becomes very low. Mathematically, a low denominator (plasma concentration) results in a **high $V_d$** [1].2. Analysis of Incorrect Options:<ul><li>Hydrophilicity: Water-soluble drugs are polar and cannot easily cross lipid bilayers. They tend to remain confined to the plasma or extracellular fluid, resulting in a **low $V_d$**.</li><li>High Protein Binding: Drugs that bind strongly to plasma proteins (like albumin) are "trapped" within the vascular compartment. This maintains a high plasma concentration, leading to a **low $V_d$**. (Conversely, high *tissue* binding increases $V_d$) [1].</li><li>Low Therapeutic Index: This refers to the safety profile of a drug (the ratio between toxic and effective doses) and has no direct physiological correlation with the volume of distribution.</li></ul>High-Yield Clinical Pearls for NEET-PG:<ul><li>Drug Example: **Chloroquine** has a massive $V_d$ (~15,000 L) because it binds extensively to tissues (retina/liver) [1].</li><li>Hemodialysis: Drugs with a high $V_d$ cannot be efficiently removed by hemodialysis because most of the drug is outside the bloodstream.</li><li>Loading Dose: $V_d$ is the primary determinant used to calculate the Loading Dose ($LD = V_d \times \text{Target Plasma Concentration}$) [3].</li><li>Aging/Obesity: In elderly or obese patients, the $V_d$ for lipophilic drugs (e.g., Diazepam) increases due to a higher body fat percentage.</li></ul>

Question 427: Efficacy of a new drug is compared with an existing drug in which phase of clinical trials?

A. Phase I
B. Phase II
C. Phase III (Correct Answer)
D. Phase IV

Explanation: **Explanation:** The primary objective of **Phase III clinical trials** is to confirm the therapeutic benefit and safety of a drug in a large patient population (1,000–3,000 patients). A critical component of this phase is the **comparative study**, where the new drug is compared against the current "Gold Standard" (existing drug) or a placebo. This establishes whether the new drug is superior or non-inferior to existing treatments, providing the necessary data for regulatory approval (NDA). **Analysis of Incorrect Options:** * **Phase I:** Focuses on **Safety and Tolerability**. It is usually conducted on a small group (20–80) of healthy volunteers to determine the Maximum Tolerated Dose (MTD) and pharmacokinetics. * **Phase II:** Focuses on **Therapeutic Efficacy and Dose-ranging**. It is conducted on a small group of patients (100–300) to see if the drug actually works for the target disease and to find the optimal dose. * **Phase IV:** This is **Post-Marketing Surveillance**. It occurs after the drug is launched to detect rare adverse effects and long-term safety in the general population. **High-Yield Clinical Pearls for NEET-PG:** * **Phase 0:** Also known as **Human Microdosing** studies; used to determine PK parameters using sub-therapeutic doses. * **Phase I Exception:** Phase I trials for cytotoxic anti-cancer drugs are conducted on **patients**, not healthy volunteers. * **Phase II:** Often called the "Proof of Concept" phase. * **Phase III:** Often referred to as "Pivotal Trials." * **Post-marketing surveillance (Phase IV):** Essential for identifying "Low-frequency" side effects (e.g., Phocomelia with Thalidomide).

Question 428: Drugs with high affinity can be used in what concentration?

A. High concentration.
B. Low concentration. (Correct Answer)
C. Moderate concentration.
D. None.

Explanation: **Explanation:** The correct answer is **B. Low concentration.** **1. Why the correct answer is right:** In pharmacology, **affinity** refers to the chemical force or the strength of the bond between a drug and its receptor. It is a measure of how easily a drug binds to its target [1]. If a drug has a **high affinity**, it possesses a strong attraction to the receptor site. Therefore, even at very **low concentrations**, a significant number of receptors will be occupied to produce the desired pharmacological effect [1], [2]. This concept is directly related to **potency**; drugs with high affinity are typically more potent, meaning they require a smaller dose (lower concentration) to achieve a specific response (e.g., $ED_{50}$) [4]. **2. Why other options are wrong:** * **A. High concentration:** Using a high-affinity drug at high concentrations would lead to excessive receptor saturation and potentially severe toxicity or side effects, as the drug binds very tightly [2]. * **C. Moderate concentration:** While a moderate concentration might work, it is not the *defining* characteristic of high-affinity drugs. The hallmark of high affinity is the ability to work effectively at minimal (low) levels. * **D. None:** This is incorrect as concentration is a fundamental variable in pharmacodynamics. **NEET-PG High-Yield Pearls:** * **Affinity vs. Intrinsic Activity:** Affinity is the ability to *bind* to a receptor; Intrinsic Activity (Efficacy) is the ability to *activate* the receptor and produce a response [3]. * **Dissociation Constant ($K_d$):** Affinity is inversely proportional to $K_d$. A **low $K_d$** indicates **high affinity** [1]. * **Potency:** On a Dose-Response Curve (DRC), a shift to the **left** indicates higher potency (and usually higher affinity), meaning the drug works at a lower concentration [4].

Question 429: The ratio of the median lethal dose to the median effective dose is the:

A. Morbidity index
B. Mortality index
C. Anesthetic ratio
D. Therapeutic index (Correct Answer)

Explanation: **Explanation:** The **Therapeutic Index (TI)** is a quantitative measurement of the relative safety of a drug. It is defined as the ratio of the dose that produces toxicity in 50% of the population (**Median Lethal Dose or $LD_{50}$**) to the dose that produces the desired clinical effect in 50% of the population (**Median Effective Dose or $ED_{50}$**). $$\text{Therapeutic Index} = \frac{LD_{50}}{ED_{50}}$$ A higher TI indicates a wider margin of safety, meaning a much larger dose is required to cause death than to achieve a cure. **Analysis of Incorrect Options:** * **Morbidity and Mortality Indices:** These are epidemiological terms used to measure the frequency of disease and death within a population, respectively; they are not used to describe drug dosage ratios. * **Anesthetic Ratio:** While related to the safety margin of anesthetic agents, it is not the standard pharmacological term for the $LD_{50}/ED_{50}$ ratio. **High-Yield Clinical Pearls for NEET-PG:** * **Narrow Therapeutic Index (NTI) Drugs:** These drugs require frequent **Therapeutic Drug Monitoring (TDM)** because small increments in dose can lead to severe toxicity. Mnemonic: **"WATT"** (**W**arfarin, **A**minoglycosides/Amphotericin B, **T**heophylline, **T**ricyclic Antidepressants) + **Lithium, Digoxin, and Phenytoin.** * **Certainty Safety Factor:** Since $LD_{50}$ and $ED_{50}$ only look at the 50% mark, the "Standard Safety Margin" ($LD_1/ED_{99}$) is often considered a more clinically relevant measure of safety. * **Penicillin** has a very high therapeutic index, while **Digoxin** has a very low (narrow) therapeutic index.

Question 430: All are true regarding protease-activated receptors, except:

A. They are a family of three seven-transmembrane proteins. (Correct Answer)
B. They are activated by thrombin.
C. They release PGE2.
D. They protect epithelial cells.

Explanation: **Explanation:** Protease-activated receptors (PARs) are a unique subfamily of **G-protein-coupled receptors (GPCRs)**. The mechanism of activation is distinct: a protease (like thrombin) cleaves a specific segment of the receptor's extracellular N-terminus, creating a "tethered ligand" that then binds to the receptor itself to initiate signaling. **1. Why Option A is the Correct Answer (The Exception):** PARs are a family of **four** seven-transmembrane proteins (**PAR-1 to PAR-4**), not three. * **PAR-1, PAR-3, and PAR-4** are primarily activated by **thrombin**. * **PAR-2** is primarily activated by **trypsin** or mast cell tryptase. **2. Analysis of Other Options:** * **Option B (Activated by Thrombin):** This is a true statement. Thrombin is the principal activator of PAR-1 (the main thrombin receptor on platelets), PAR-3, and PAR-4. This is a critical step in platelet aggregation and clot formation. * **Option C (Release PGE2):** This is true. Activation of PARs (especially in the gastric mucosa and airways) triggers the release of cytoprotective mediators like **Prostaglandin E2 (PGE2)** and nitric oxide. * **Option D (Protect epithelial cells):** This is true. In the gastrointestinal tract, PAR activation (specifically PAR-2) promotes epithelial cell survival, mucus secretion, and mucosal repair, serving a protective "sensor" function against luminal proteases. **High-Yield Clinical Pearls for NEET-PG:** * **Vorapaxar:** A competitive antagonist of **PAR-1**. It is used clinically as an antiplatelet drug to reduce thrombotic cardiovascular events in patients with a history of MI or peripheral arterial disease. * **Irreversibility:** Because the receptor is activated by proteolytic cleavage (a covalent change), a single receptor molecule can only be activated once, making the mechanism effectively irreversible until a new receptor is synthesized.

Practice by Chapter

Pharmacokinetics: Absorption and Distribution

Practice Questions

Pharmacokinetics: Metabolism and Excretion

Practice Questions

Pharmacodynamics and Receptor Theory

Practice Questions

Drug-Receptor Interactions and Dose-Response

Practice Questions

Pharmacogenetics and Personalized Medicine

Practice Questions

Adverse Drug Reactions and Toxicity

Practice Questions

Drug Interactions

Practice Questions

Drug Development and Regulation

Practice Questions

Pediatric and Geriatric Pharmacology

Practice Questions

Placental Transfer and Lactation

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free